Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel application of nucleic acid vaccine expressing hepatitis B surface antigen

A surface antigen, hepatitis B virus technology, applied in the direction of antiviral agents, medical preparations containing active ingredients, antibody medical ingredients, etc., can solve problems such as insufficient immunogenicity and inability to induce cellular immunity.

Inactive Publication Date: 2015-08-12
卢山
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But these vaccines still have the following disadvantages: 1) immunogenicity is not high enough; 2) cellular immunity cannot be induced
So far in the world, all immune adjuvants, including aluminum adjuvants, are non-antigen-specific, that is, they can amplify the immune effect through a common immunological basic mechanism, but they are not specific to a specific pathogen

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel application of nucleic acid vaccine expressing hepatitis B surface antigen
  • Novel application of nucleic acid vaccine expressing hepatitis B surface antigen
  • Novel application of nucleic acid vaccine expressing hepatitis B surface antigen

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Detailed preparation method of nucleic acid vaccine and its gene sequence.

[0042] 1) Construction of HBV surface antigen nucleic acid vaccine ( figure 1 )

[0043] Based on the gene sequences of more than 20 HBV adr subtype surface antigens on Genbank, we designed the consensus sequence adr-HBs-Cons of HBV adr subtype surface antigen, and according to the sequence of higher mammals, especially humans (Homo sapiens) The codon preference was optimized with Accelrys software to enable better expression in eukaryotic cells without changing the primary structure of the adr-HBs-Cons protein. Our codon optimization also avoids modification of ciseopathic element sequences such as TATA boxes, ribosome entry sites, AT- or GC-rich sequence sites, sequence elements, potential splicing codons, etc. The gene sequence, shown as SEQ ID NO.1, was synthesized by Geneart Company of Germany (Regensburg, Germany), and loaded into vector pGA4 to obtain plasmid pGA4 / adr-HBs-cons / opt. Us...

Embodiment 2

[0045] Example 2. The target plasmid was extracted with Qiagen Plasmid Mega Kit produced by Qiagen.

[0046] 1) Aspirate 5 μL of the correctly identified bacterial preservation solution and inoculate it into 5 ml of LB culture solution containing kanatoxin, grow overnight at 37° C., 200 rpm. The next day, move the bacteria to a 250ml centrifuge bottle, centrifuge at 6000g at 4°C for 15min, discard the supernatant, and collect the bacteria.

[0047] 4) Resuspend the bacterial pellet in 50ml of buffer P1 and shake repeatedly until no bacterial clumps can be seen and all the bacteria are resuspended in the solution.

[0048] 5) Add 50ml of buffer P2 into the centrifuge bottle, gently invert it 5-6 times, the solution turns blue, and let it stand for 5 minutes.

[0049] 6) Add 50ml of buffer P3 into the above mixed liquid, gently invert 5-6 times, the blue solution disappears, the solution is layered, the upper layer is a solid milky white mass, and the lower layer is a clear liq...

Embodiment 3

[0059] Example 3. Cell Transfection

[0060] 293T cells were cultured in double-antibody DMEM high-glucose medium containing 10% fetal bovine serum at 37°C, 5% CO 2 Cultivate in a saturated humidity incubator until the logarithmic growth phase, digest with 2.5g / L trypsin, and use 5.0×10 6 Cells (8 mL) were inoculated in 100 mm culture dishes, and transfection began when they grew to 80% confluence. Cell transfection was carried out according to the PEI transfection method. Take 75 μL of PEI and add it to 750 μL of double-antibody-containing DMEM high-glucose medium, and another 15.0 μg of pSW3891 / adr-HBs-cons / opt recombinant expression plasmid was added to the above culture medium. Gently mix, incubate at room temperature for 15 minutes, then add the PEI / DNA complex to the culture flask and shake gently to mix evenly. At the same time, cells transfected with pSW3891 empty plasmid are used as a negative control, and can be replaced after 10 hours without serum containing doubl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses novel application of a nucleic acid vaccine expressing hepatitis B surface antigen, which belongs to the field of biological medicine. The invention provides application of the nucleic acid vaccine expressing the hepatitis B surface antigen as a specific adjuvant for a hepatitis B vaccine. As for chemical nature, the specific adjuvant directed at the hepatitis B surface antigen is the nucleic acid vaccine capable of expressing the hepatitis B surface antigen in cells in the human body. The specific adjuvant directed at the hepatitis B surface antigen can be cooperatively used with a commercial subunit hepatitis B vaccine and improves the immune effect of the subunit vaccine.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to a new application of a nucleic acid vaccine expressing the surface antigen of hepatitis B virus. technical background [0002] Hepatitis B virus infection is one of the major diseases that endanger human health around the world. According to the statistics of the World Health Organization, there are about 2 billion people infected with hepatitis B virus in the world, and 30 million of them are chronic hepatitis B carriers. About 600,000 people die from hepatitis B infection-related diseases (such as liver cirrhosis and liver cancer) every year. China is an area with a high incidence of hepatitis B infection. According to statistics in 2012, there are nearly 120 million infected people nationwide. Hepatitis B subunit vaccine is currently an effective means of preventing hepatitis B virus infection. Most hepatitis B subunit vaccines already contain conventional adjuvant aluminum hydroxide....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/39A61K48/00A61K39/29A61P1/16A61P31/20
Inventor 卢山张璐王世霞
Owner 卢山